Abu Dhabi partners with a US biotechnology company to develop advanced gene-editing therapies. June 25, 2026 The new collaboration seeks to advance the development of treatments for rare and inherited diseases. Abu Dhabi has taken another significant step in advancing precision medicine after the Department of Health - Abu Dhabi (DoH), M42, and US-based Mammoth Biosciences signed a memorandum of understanding (MoU) to develop gene-editing therapies for rare and inherited diseases. The agreement was announced at the BIO International Convention 2026 in San Diego and is aimed at strengthening Abu Dhabi's growing life sciences sector by supporting clinical research, advanced therapy manufacturing, and scientific innovation. Officials said the collaboration builds on the emirate's ongoing investments in genomics and precision medicine, with the goal of translating genetic research into treatments that can benefit patients in the UAE and globally. The partnership will leverage insights from the Emirati Genome Programme to support the development of next-generation therapies for inherited diseases, while also expanding research and manufacturing capabilities in Abu Dhabi. Driving the future of precision medicine. Dr Noura Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, said the partnership reflects the emirate's long-term commitment to advancing healthcare innovation. "Abu Dhabi has built a strong foundation in genomics and precision medicine through sustained investments in research and innovation. The next step is translating these insights into therapies that can address some of the most complex diseases affecting communities in our region and globally," she said. Under the agreement, the Department of Health - Abu Dhabi will provide the regulatory and research framework, while M42 will contribute its genomics expertise, healthcare network, and clinical research infrastructure. Mammoth Biosciences will bring its CRISPR-based gene-editing technology to the collaboration. Dr Fahed Al Marzooqi, Chief Executive Officer of Integrated Health Solutions at M42, said the Emirati Genome Programme has generated valuable insights into the health needs of the local population. "Through this collaboration, we are building on that foundation by supporting the development of advanced therapies while strengthening Abu Dhabi's research, clinical, and manufacturing capabilities," he said. Building local expertise and manufacturing capacity. Mammoth Biosciences, co-founded by Nobel Prize-winning scientist Jennifer Doudna, develops gene-editing technologies aimed at treating inherited diseases by correcting genetic mutations rather than merely managing symptoms. The agreement also includes plans to introduce Mammoth's lead clinical candidate, MB-111, into Abu Dhabi's clinical research ecosystem and support advanced gene-therapy trials in the emirate. It also outlines plans to develop advanced therapy manufacturing capabilities, starting with lipid nanoparticle production and later expanding into fully integrated manufacturing facilities. In addition, the partnership will support training programmes designed to build local expertise in CRISPR-based gene-editing technologies and strengthen the UAE's specialised healthcare workforce. The collaboration aligns with Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Cluster, which aims to accelerate healthcare innovation by integrating research, clinical development, manufacturing, and commercialisation within a unified ecosystem. Officials said the agreement represents another milestone in Abu Dhabi's efforts to establish itself as a global hub for life sciences, advanced therapies, and precision medicine.

Mammoth Biosciences to present at 44th Annual J.P. Morgan Healthcare Conference. BRISBANE, Calif. - (BUSINESS WIRE) - #CRISPR - Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing platform to create potential one-time curative therapies, today announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference. Trevor Martin, Ph.D., co-founder and CEO, will provide a corporate overview with key business updates related to Mammoth Biosciences' pipeline and platform on Thursday, January 15 at 7.30 am PT in San Francisco. About Mammoth Biosciences Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company's ultracompact systems are designed to be more specific and packageable to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, reverse transcriptase editing, and epigenetic editing. The company is building out its wholly owned pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology platform. Mammoth Biosciences' deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the promise of CRISPR technologies. For more information, please visit www.mammoth.bio or follow Mammoth on LinkedIn or X. Media Contact: Mohana Ray Email: [email protected] Phone: 312-506-5210